BVF as of Sept. 30, 2016
Portfolio Holdings for BVF
BVF holds 29 positions in its portfolio as reported in the September 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 15.5 | $82M | 2.8M | 29.70 | |
| Chemocentryx | 9.2 | $49M | 8.1M | 6.04 | |
| Cytokinetics (CYTK) | 8.7 | $46M | 5.0M | 9.18 | |
| Array BioPharma | 8.2 | $44M | 6.5M | 6.75 | |
| Cascadian Therapeutics | 5.8 | $31M | 19M | 1.64 | |
| Forward Pharma A/s | 5.5 | $29M | 1.4M | 21.00 | |
| Colucid Pharmaceuticals | 5.5 | $29M | 763k | 38.15 | |
| Concert Pharmaceuticals I equity | 5.2 | $28M | 2.7M | 10.11 | |
| Xenon Pharmaceuticals (XENE) | 4.8 | $25M | 3.1M | 8.10 | |
| Oncomed Pharmaceuticals | 3.9 | $21M | 1.8M | 11.43 | |
| Glycomimetics | 3.3 | $17M | 2.4M | 7.15 | |
| Cti Biopharma | 3.1 | $17M | 45M | 0.37 | |
| Tobira Therapeutics Inc Common Stock Usd 0.0001 | 3.0 | $16M | 399k | 39.74 | |
| Nivalis Therapeutics | 2.6 | $14M | 1.7M | 8.13 | |
| ArQule | 2.5 | $13M | 7.4M | 1.79 | |
| Cytomx Therapeutics (CTMX) | 1.8 | $9.3M | 592k | 15.68 | |
| Immune Design | 1.7 | $9.1M | 1.2M | 7.58 | |
| GTx | 1.7 | $9.0M | 12M | 0.78 | |
| Infinity Pharmaceuticals (INFIQ) | 1.5 | $8.0M | 5.1M | 1.56 | |
| Protagonist Therapeutics (PTGX) | 1.5 | $7.9M | 375k | 21.13 | |
| Esperion Therapeutics (ESPR) | 1.3 | $6.8M | 494k | 13.85 | |
| Aduro Biotech | 1.2 | $6.2M | 501k | 12.43 | |
| Sunesis Pharmaceuticals Inc Ne | 0.6 | $3.2M | 730k | 4.37 | |
| Orexigen Therapeutics Inc. 144a 2 3/4% Due 12/1/2020 Jd1 note 2.750%12/0 | 0.5 | $2.6M | 10M | 0.26 | |
| Orexigen Therapeutics | 0.5 | $2.4M | 735k | 3.32 | |
| Pain Therapeutics | 0.4 | $2.3M | 2.3M | 1.00 | |
| Pieris Pharmaceuticals | 0.3 | $1.9M | 1.0M | 1.83 | |
| Catalyst Biosciences | 0.2 | $1.0M | 866k | 1.21 | |
| Globeimmune (GBIM) | 0.1 | $822k | 658k | 1.25 |
